Trying to hear what's not being said
October 6, 2025 Leave a comment
While specific U.S. biotech’s are held in client portfolios, the broader sector has seen the ‘fat part’ of the trade.
An extreme low in the S&P Biotech ETF (XBI) was mentioned in the April 6, 2025 edition of my Macro Extremes weekly note.
and an overbought extreme was highlighted in yesterdays edition.
For now, ~37% over 6 months will do.
I’ll leave the next 10% for someone else.
October 6, 2025
rob@karriasset.com.au
December 20, 2024 Leave a comment
My note from 1 month ago called for a bounce in biotech prices but re-iterated my view that I still expect prices to ladder their way lower.
In that note, I referenced the iShares Biotech ETF (IBB).
And so, from the day of my note’s release (November 19, 2024), it did commence its climb, eventually rising 7.5% and recovering 50% of the recent decline.
Since then, the IBB ETF has fallen again, erasing those gains and has since making a new ‘lower low’.
And I’m still calling IBB down to the $100 mark. It is $131 today.
December 20, 2024
rob@karriasset.com.au
November 19, 2024 Leave a comment
Last week’s abrupt decline in the U.S. #biotech indices look like the beginning of a larger decline.
It could be a dark winter while political machinations sort themselves out.
For some reference, while the iShares Biotech ETF #IBB will likely bounce in the near term, I’ll look for it to eventually trade down slightly below the $100 mark.
November 19, 2024
rob@karriasset.com.au
rob zdravevski's blog 